Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy
Abstract
The expansion of hematopoietic stem cells carrying recurrent somatic mutations, termed clonal hematopoiesis (CH), is common in elderly individuals and is associated with increased risk of myeloid malignancy and all-cause mortality. Though chemotherapy is a known risk factor for developing CH, how myelosuppressive therapies affect the short-term dynamics of CH remains incompletely understood. Most studies have been limited by retrospective design, heterogeneous patient populations, varied techniques to identifying CH, and analysis of single timepoints.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 12, 2023
- Source ID
- 10.1093/jnci/djad065
Entities
People
- Abhay Tiwari
- Adriana Perilla-glen
- Ameer S. Basta
- Andrew R Wong
- Annette S Kim
- Christina Mayerhofer
- Christopher J. Gibson
- Elizabeth A. Mittendorf
- Erica L Mayer
- Harold J. Burstein
- Heather A. Parsons
- Judith O. Hopkins
- Meredith G. Faggen
- Mina S. Sedrak
- Nabihah Tayob
- Natalie F. Sinclair
- Paulina B. Lange
- Peter G. Miller
- Rachel A Freedman
- Ruth I. Lederman
- Sandra S McAllister
- Tianyu Li
- Wendy Y. Chen
Organizations
- American Cancer Society
- Brigham and Women's Hospital
- City of Hope National Medical Center
- Dana–Farber Cancer Institute
- Edward P. Evans Foundation
- German Research Foundation
- Harvard Medical School
- Harvard Stem Cell Institute
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- National Cancer Institute
- National Institute on Aging
- United States Department of Defense